After harsh light, a cheaper version of EpiPen from Mylan

December 16, 2016 by Tom Murphy
In this July 8, 2016, file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif. Mylan has started selling a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted Congressional inquiries. (AP Photo/Rich Pedroncelli, File)

Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.

The potential cost savings will depend in part on a patient's insurance coverage and qualifications for discount and assistance programs that the drugmaker also provides.

For Mylan, the benefit from its long-promised generic is more certain: It is expected to generate millions of dollars in revenue while also protecting the drugmaker's market share against competition.

Mylan NV said Friday that it will charge $300 for the generic version of its life-saving injections, which come in a two pack. The generic version will begin to reach retail pharmacies next week.

The list price of an EpiPen two-pack, which is stocked by schools and parents of children with severe allergies, now tops $600, an increase of more than 500 percent since 2007, when Mylan bought rights to the drug.

EpiPens are used in emergencies to stop anaphylaxis, the potentially fatal allergic reactions to insect bites and stings and foods like nuts and eggs. People usually keep multiple EpiPens handy at home, school or work. But the syringes, prefilled with the hormone epinephrine, expire after a year.

Criticism of the branded drug's list price started snowballing last summer when parents doing back-to-school shopping encountered sticker shock at the pharmacy counter and began protesting to politicians and on social media.

In September, a Congressional panel grilled Mylan CEO Healthier Bresch about the soaring cost, which she has blamed in part on insurers, pharmacy benefits managers and other middlemen that stand between the drugmaker and the customer.

Mylan has expanded the financial aid it offers to EpiPen customers since the pricing criticism grew, but it hasn't budged on the drug's price. It said in August that it was doubling the limit for eligibility for its patient assistance program, so a family of four making up to $97,200 would pay nothing out of pocket for EpiPens.

A company spokeswoman confirmed Friday that the assistance also will apply to the generic version.

Mylan also offers $300 copay cards for the brand-name version, to help customers with high out-of-pocket expenses. It's also providing a $25 discount for customers buying the generic version

But uninsured patients and those on the government-funded Medicaid and Medicare programs don't qualify.

Critics have dismissed these discounts and assistance programs. They say many customers won't use or qualify for them, and they argue that these programs have little impact on the bill that employer or insurers pay, which can affect the price of health insurance.

Explore further: Mylan to pay $465 mn over EpiPen overcharges to Medicaid

Related Stories

Mylan to pay $465 mn over EpiPen overcharges to Medicaid

October 7, 2016
Mylan will pay $465 million to resolve accusations from some regulators that it overbilled the federal Medicaid program for the EpiPen allergy medication, the drugmaker announced Friday.

Mylan CEO to testify in hearing on EpiPen price increases

September 14, 2016
The head of the pharmaceutical company Mylan will face lawmakers' questions at a hearing next week on steep price increases for its life-saving EpiPen injector device.

New York state opens antitrust probe of Mylan's EpiPen

September 6, 2016
New York state has launched an antitrust probe into Mylan's sale of the EpiPen anti-allergy injector to local school systems, New York's attorney general announced Tuesday.

Federal government: Mylan has been overcharging for EpiPens

October 6, 2016
Even the federal government is apparently paying too much for EpiPens, along with angry patients and insurers.

Mylan opens $27.14 billion hostile bid for Perrigo

September 15, 2015
Shares of Mylan are edging up before the opening bell after the pharmaceutical company went ahead with its hostile, $27.14 billion bid for Perrigo.

Clinton offers plan to prevent 'excessive' drug price hikes

September 2, 2016
Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.

Recommended for you

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.